Pharmacokinetics and effects on plasma retinol concentrations of 13-cis-retinoic acid in melanoma patients
1997

Effects of 13-cis-retinoic acid on melanoma patients

Sample size: 14 publication Evidence: moderate

Author Information

Author(s): F Formelli, E Cavadini, L Mascheroni, F Belli, N Cascinelli

Primary Institution: Istituto Nazionale per lo Studio e la Cura dei Tumori

Hypothesis

The study aims to evaluate the pharmacokinetics of 13-cis-retinoic acid and its effects on retinol plasma levels in melanoma patients.

Conclusion

The study found that 13-cis-retinoic acid treatment led to a temporary reduction in retinol plasma levels in melanoma patients.

Supporting Evidence

  • Maximum 13-cis-retinoic acid blood concentrations occurred 4 hours after administration.
  • Retinol plasma levels decreased by approximately 20% shortly after 13-cis-retinoic acid dosing.
  • The pharmacokinetics of 13-cis-retinoic acid did not change after multiple doses.

Takeaway

This study looked at how a medicine called 13-cis-retinoic acid affects vitamin A levels in people with skin cancer.

Methodology

Patients were treated with either 20 mg or 40 mg of 13-cis-retinoic acid and their blood was sampled to measure drug and retinol levels.

Limitations

The study had a small sample size and variability in drug absorption among patients.

Participant Demographics

Patients were melanoma patients with regional node metastases who had undergone radical surgery.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication